Filing Details
Theravance Biopharma, Inc. (NASDAQ:TBPH) filed a Form 8-K with the Securities and Exchange Commission on June 29, 2026, disclosing a material event.
8k filedNASDAQ:TBPH
Theravance Biopharma, Inc. (TBPH) Reports Material Event to SEC
Filing Details Theravance Biopharma, Inc. (NASDAQ:TBPH) filed a Form 8-K with the Securities and Exchange Commission on June 29, 2026, disclosing a material event. Market Context…
Market Context
Theravance Biopharma, Inc.'s stock currently trades at $17.06 with a market capitalization of $895.4M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Theravance Biopharma, Inc.'s stock.
All SEC filings for Theravance Biopharma, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View TBPH Stock Page
Frequently Asked Questions
Where can I read TBPH's SEC filings?
Browse all filings on our TBPH SEC filings page.
What types of SEC filings does Theravance Biopharma, Inc. file?
Public companies like Theravance Biopharma, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.
